Experimental work posits that acute ischaemic events trigger haematopoietic activity, driving monocytosis, and atherogenesis. Considering the chronic low-grade inflammatory state in atherosclerosis, we hypothesized that haematopoietic hyperactivity is a persistent feature in cardiovascular disease (CVD). Therefore, we aimed to assess the activity of haematopoietic organs and haematopoietic stem and progenitor cells (HSPCs) in humans.
Introduction
Atherosclerosis is a chronic disease of the arterial wall, in which lipoproteins and inflammation are closely intertwined. 1 Early lesions arise when, among other atherogenic risk factors, elevated LDL particles induce endothelial dysfunction at susceptible arterial sites. The latter allows for LDL accumulation in the intimal space followed by modification into its oxidized forms (oxLDL). In parallel, inflammatory cells, of which monocytes/macrophages are the most abundant, are recruited to the intima and form foam cells after taking up oxLDL. 1 Ultimately, these fatty streaks advance into atherosclerotic plaques, predominantly driven by low-grade inflammatory responses. 1 A unifying view posits the bone marrow as the primary site of monocyte production; however, in an inflammatory disorder, other lymphoid tissues, such as the spleen, can also produce monocytes. 2, 3 In the context of atherosclerosis, murine studies showed that an acute ischaemic event, such as myocardial infarction (MI) or stroke, induced the release of haematopoietic stem and progenitor cells (HSPCs) from bone marrow niches via sympathetic nervous signaling. 4 A large number of HSPCs seeded the spleen, to subsequently serve as an extramedullary production site of monocytes. 5, 6 Moreover, the systemic oversupply of inflammatory monocytes aggravated pre-existing atherosclerotic lesions. 4 Recent clinical studies validated the enhanced haematopoietic activity in MI patients, proposing the acute ischaemic event as its trigger. 7 -9 However, while signs and symptoms of an ischaemic event fade within hours to days, the low-grade inflammatory state might be chronically present in cardiovascular disease (CVD) patients, as suggested by both experimental studies showing the high turn-over of inflammatory lesional cells, 6, 10 and clinical imaging corroborating continuous influx of immune cells into advanced lesions. 11 Therefore, we hypothesized that haematopoietic activity is chronically enhanced in patients with atherosclerosis.
To this end, we first performed 18 F-fluorodeoxyglucose positron emission tomographic with computed tomography ( 18 F-FDG PET/ CT) imaging in patients with stable atherosclerotic CVD and matched control subjects to assess the metabolic activity of both the arterial wall and haematopoietic tissues. Next, we evaluated the progenitor potential of HSPCs that had been harvested from atherosclerotic CVD patients and matched control patients, both identified from a cohort of cancer patients. Finally, we co-incubated healthy donor-derived HSPCs with native and oxidized lipoproteins in vitro and assessed changes in progenitor potential and phenotype.
Methods

Study subjects
All subjects provided informed consent, and studies were conducted according to the principles of the International Conference on Harmonization -Good Clinical Practice guidelines. Patients in the PET study were characterized by stable atherosclerotic CVD, which was defined as a positive history of an ischaemic event .1 year ago (myocardial or cerebral infarction due to significant coronary or carotid artery stenosis, respectively) and stable medication use for .3 months prior to inclusion. In addition, patients had been diagnosed with elevated LDL cholesterol levels due to familial hypercholesterolaemia. For comparison, subjects matched for age, gender, and BMI though without a history for CVD underwent PET imaging. In a cohort of haemato-oncological patients (n ¼ 953), we identified patients with documented atherosclerotic CVD .1 year prior to (i) the diagnosis of a malignancy and (ii) the harvesting of HSPCs in the context of an autologous stem cell transplantation (autoSCT), and selected control patients without known CVD, matched for age, gender, BMI, and indication for autoSCT. In general, subjects with (pre)diabetes were excluded.
F-fluorodeoxyglucose positron emission tomographic with computed tomography imaging
Positron emission tomographic with computed tomography scans were performed on a dedicated scanner (Philips, Best, the Netherlands). Subjects fasted for at least 6 h prior to infusion of 200 MBq of 18 F-FDG (5.5 mCi). Ninety minutes after 18 F-FDG infusion, PET imaging was initiated with a low-dose, non-contrast enhanced CT for attenuation correction and anatomic co-registration (slice thickness 3 mm). Positron emission tomographic with computed tomography images were analysed with dedicated analysis software (OsiriX, Geneva, Switzerland; http://www.osirix-viewer.com/). Two readers (F.M.v.d.V., Y.K.) analysed all images to assess inter-observer variability. One reader (F.M.v.d.V.) analysed all images twice to assess intra-observer variability. Readers were blinded for patient data.
The maximal target-to-background-ratios (TBR max ) in the carotids were determined as described previously. 12 The carotid TBR max represents the average of the left and right carotid arteries. The mean and maximal standard uptake values (SUV max and SUV mean ) in the BM and spleen was determined as previously described. 9 In brief, SUV max for each vertebra (T1 to L5) was assessed, and BM activity was calculated as the mean of SUV max of all vertebrae. For the spleen, SUV max was assessed in axial, sagittal, and coronal planes, and splenic activity was calculated as the mean of SUV max values of the three planes. A similar approach was used for the SUV mean .
Coronary artery calcium score
Computed tomography scans were used to determine the Agatston score, the coronary artery calcium (CAC) score. In a manually set volume of interest, all pixels with intensity .130 HU were selected. Connected areas of these threshold pixels were constructed. In vitro model using healthy haematopoietic stem and progenitor cells
Leukapheresis material of healthy donors treated with G-CSF (5 -10 mg/kg/day) was used to obtain CD34+ cells. These cells were enriched by magnetic cell sorting according to the manufacturer instructions (Miltenyi Biotec, Bergisch Gladbach, Germany), resulting in a purity of .90%, as determined by flow cytometry. CD34+ cells were plated in 96-well plates (Thermo Scientific, Waltham, MA, USA) at 30 000 cells/well and kept in maintenance cocktail of 100 mL StemSpan (Stemcell Technologies) per well, supplemented with 100 U/mL penicillin, 100 mg/mL streptomycin, 50 ng/mL n-plate, 100 ng/mL stem cell factor, and 100 ng/mL Flt3. At Day 0, CD34+ cells were stimulated with control medium, native LDL (nLDL) or oxLDL (Alfa Aesar, for both 10 mg/mL). In inhibition experiments using E06 (1 nM), the above three stimuli were co-incubated with the inhibitor. Limulus amebocyte lysate assay showed negligible endotoxin levels (,0.05 EU/mL) in the stimuli. All cells were cultured at 378C at 5% CO 2 . At Day 7, cells were counted and flow cytometric and CFU-GM assays were performed. The cultured cells were counted at Day 7 by flow cytometric assays with Cyto-Cal fluorescent beads (Thermo Scientific, Fremont, CA, USA), using a CANTO ll + HTS flow cytometer (BD) and were characterized for surface expression of various receptors by flow cytometry. Cells were washed and resuspended in PBS containing 0.2% BSA prior to incubation (20 min at RT) with the following monoclonal antibodies. Antibodies purchases from BD, San Jose CA: CD13-PE (clone WM15), F.M. van der Valk et al.
CD14-PerCP-Cy5.5 (clone M5E2), CD33-PE (clone WM53), CD34-PECy7 (clone 8G12), CD38-APC (clone HB7), CD45-PB (clone H130), and CD192 (CCR2)-Alexa-Fluor 647 (clone 48607). Purchased from Sanquin, Amsterdam, The Netherlands: CD16-FITC (clone CLB-Fc-gran/1, 5D2) and CD36-FITC (clone M1613). Purchased from Dako, Cambridgeshire, UK: CD41-FITC (clone 5B12). A minimum of 10 000 cells were recorded, using a CANTO ll + HTS flow cytometer (BD).
For CFU-GM assays, cultured cells were plated in duplicate 0.5 mL in 24-well plates (Corning, NY, USA) at a concentration of 150 cells/well, respectively, in MethoCult H4434 (StemCell Technologies). Cultures were incubated for 12 -14 days at 378C at 5% CO 2 .Colony-forming units-granulocyte/monocyte, colonies were scored in triplo by microscopy (Olympus CK2, Shinjuku, Tokyo, Japan).
Statistical analysis
Continuous variables are expressed as mean + SD or median and range (either interquartile range [IQR] or 25th-75th percentile), and categorical variables as percentage and number (n). Differences in PET imaging parameters between groups were assessed with a multivariable model to account for cardiovascular risk factors. Correlations were assessed using Spearman's tests. The agreement between 18 F-FDG PET/CT analyses was assessed using intraclass correlation coefficients (ICCs, r).
Differences in G-CSF harvested cells between patients were assessed using nonparametric Mann-Whitney U tests. In vitro stimulation assays were repeated at least five times, and the differences between control, nLDL, and oxLDL stimulations were assessed using a Kruskal -Wallis analysis. P-values were tested two sided, and ,0.05 was defined as statistically significant. All data were analysed using SPSS version 21.0 (SPSS Inc., Chicago, IL, USA).
Results
Enhanced haematopoietic activity in cardiovascular disease patients Increased haematopoietic activity in atherosclerosis acid, and B-blockage, and C-reactive protein (CRP) levels were higher in patients. Other characteristics were comparable between groups ( Table 1) . Figure 1A -C illustrates the multiple levels at which 18 F-FDG uptake was assessed in both patients and matched controls. Carotid 18 F-FDG uptake was increased in patients compared with controls (1.95 + 0.33 vs. 1.58 + 0.20, P , 0.001, Figure 1D ). In addition, 18 F-FDG uptake in the spleen and bone marrow was also higher in patients compared with controls ( Figure 1E and F, F-FDG uptake and inflammatory biomarkers (MCP-1, TNFa, and IL-6) or traditional cardiovascular risk factors was observed. Finally, the intra-and inter-observer agreement was excellent for SUV values in bone marrow or spleen, as indicated by the ICCs of .0.94 with narrow 95% confidence intervals (see Supplementary material online, Table S2 ).
Increased progenitor potential of haematopoietic stem and progenitor cells in cardiovascular disease patients
Provoked by the enhanced bone marrow 18 F-FDG uptake in CVD patients in vivo, we screened a cohort of 953 cancer patients in whom HSPCs had been harvested via G-CSF. We identified 18 subjects with documented atherosclerosis, consisting of MI with fluorodeoxyglucose; CVD, cardiovascular disease; SUV, standardized uptake values; TBR, target-to-background ratio. Continuous data are shown as mean + SD. significant coronary artery stenosis or ischaemic stroke with significant carotid artery stenosis, having occurred 17 months (IQR 5 months) prior to HSPCs harvesting. The latter was performed in the context of an autoSCT due to the diagnosis of a multiple myeloma (61%) or relapse of non-Hodgkin lymphoma (39%) in disease stages I-III. For comparison, we selected 30 control patients without known CVD, matched for age, gender, BMI, and indication for autoSCT (53% multiple myeloma and 47% relapse of non-Hodgkin lymphoma, in matched disease stages, P ¼ 0.886). Clinical characteristics at the time of HSPCs harvesting are listed in Table 3 . Conform secondary prevention management all CVD patients used lipid lowering, ACE-inhibition, acetylsalicylic acid, and B-blockage, whereas control subjects did not. Glucose, kidney, and liver function were comparable between groups. Lipid profiles were not available. In addition, Supplementary material online, Table S3 shows the agreement between both CVD patient cohorts.
Whereas the percentage of CD34 + cells was comparable between groups ( Figure 2A ; P ¼ 0.744), the CFU-GM capacity of the G-CSF HSPCs harvested from CVD patients was 1.6-fold higher compared with control patients (0.31 + 0.18 vs. 0.19 + 0.07, P , 0.001; Figure 2B ).
Lipid risk factors change function and phenotype of haematopoietic stem and progenitor cells in vitro
Considering the correlation between bone marrow 18 F-FDG uptake and LDLc, we cultured unrelated healthy donor G-CSF harvested HSPCs (CD34+ cells) with either native LDL (nLDL) or oxidized LDL (oxLDL). After 7 days of co-incubation, the normalized cell count was not different between stimuli (P ¼ 0.444; Figure 3A ). However, the normalized progenitor capacity, assessed with CFU-GM ( Figure 3B ), was 1.5-fold higher after co-incubation with oxLDL compared with control (P ¼ 0.002; Figure 3C ). In addition, we applied the monoclonal antibody E06, which blocks the phosphocholine (PC) headgroup of oxidized phospholipids, and not native phospholipids. 13 -15 Blockage of the oxidized phospholipid load on oxLDL via E06 robustly inhibited the effect of oxLDL on normalized progenitor potential (P ¼ 0.001; Figure 3D ). Next to CFU-GM capacity, flow cytometric assays were performed to determine the phenotypic changes after nLDL or oxLDL co-incubation. No changes in the expression of CD41, CD13/33, or CD36 were observed (see Supplementary material online, Figure S1 ), whereas the cells showed a myeloid bias after 7 days of oxLDL co-incubation as indicated by the significant increased expression of CD14/CD16 (P ¼ 0.002) and borderline significant increased C -C chemokine receptor type 2 (CCR2; P ¼ 0.051) ( Figure 3E-G) .
Discussion
Here, we report that patients with stable atherosclerotic CVD have a high metabolic activity of the carotid arterial wall, as well as haematopoietic tissues in vivo. In addition, we show that HSPCs have a higher proliferative capacity ex vivo when obtained from patients with atherosclerotic CVD, compared with those without known CVD. In vitro, this enhanced proliferative potential and myeloid differentiation bias was substantiated in healthy HSPCs by coincubation with oxLDL; the oxidized phospholipid antibody E06 could inhibit this adverse effect. Collectively, these findings support the hypothesis that haematopoietic activity is chronically enhanced in patients with table atherosclerotic CVD.
Haematopoietic stem and progenitor cell number and function in cardiovascular disease patients
Previously, PET imaging studies demonstrated an increased bone marrow and splenic activity in patients with CVD. 7 -9 Whereas these studies all focused on the (semi)-acute phase following an MI, 7 -9 we now show that .12 months after the CVD event patients still exhibit higher activity of haematopoietic tissues despite CVD guideline-based management.
What does the chronically increased 18 F-FDG uptake in haematopoietic tissues imply for the patient? In general, cellular accumulation of 18 F-FDG is increased in pro-inflammatory, hypoxic as well as rapidly proliferating cells. 16 In the present stable condition, we can speculate that the 18 F-FDG in haematopoietic tissues reflects an increased proliferative rate, since HSPCs harvested from patients with Figure 3 Increased progenitor potential and myeloid differentiation bias induced by oxidized LDL. Bar graphs showing (A) no differences (P ¼ 0.444) in the cell counts after healthy haematopoietic stem and progenitor cells were co-incubated for 7 days with control medium (black bars), native LDL (10 mg/mL, light grey bars), or oxidized LDL (10 mg/mL, dark grey bars), whereas (B -D) the colony-forming units-granulocyte/ monocyte capacity, as illustrated by the microscopy image (B), increased upon co-incubation with oxidized LDL (P ¼ 0.002) (C ), which is inhibited by the antibody E06 (P ¼ 0.001) (D), and (E -G) gating strategy with accompanying results showing that the expression of CD14, CD16, and CCR2 was increased after 7 days of haematopoietic stem and progenitor cells co-incubation with oxidized LDL (P ¼ 0.002 and 0.051, respectively). Assays were performed at least eight times. CFU-GM, colony-forming units-granulocyte/monocyte; CCR2, C -C chemokine receptor type 2; HSPCs, haematopoietic stem and progenitor cells; nLDL, native low-density lipoprotein; oxLDL, oxidized LDL.
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CVD also showed an increased proliferative capacity of the GM-precursor cells. A prospective study combining PET imaging with HSPC harvesting is warranted, however, to corroborate this concept.
Besides the increased metabolic activity, we also show an enhanced functional capacity of HSPCs harvested from CVD patients compared with controls. During the last decade, differences in both number and function of circulating CD34+ cells have been reported. Thus, in patients following an acute MI, the number of endogenous circulating progenitors was significantly increased compared with controls. 17 This phasic increase in number fell significantly within 60 days after the acute event. 17 Such a transient response of haematopoietic cells following an acute ischaemic event has subsequently been corroborated in patients following either a myocardial 18 -20 or a cerebral 21, 22 infarction. Interestingly, despite normalization of cell number, we observe functional changes of CD34+ cells persisting .12 months after the acute event. Whereas the clinical relevance of a tonic haematopoietic activity warrants further validation, animal studies have indicated that the increased activity of HSPCs can promote features characteristic of vulnerable atherosclerotic lesions. 23 In addition, whether repeating acute events or long-lasting chronic stimulation could also exhaust the bone marrow 24 warrants further studies.
Causes of chronic haematopoietic activity in cardiovascular disease
Murine ligation studies evidenced that in the acute phase following an MI, anxiety, pain, and impaired left ventricular function promote sympathetic nervous signalling, proposing an important role for the b3-adrenoceptor 4 in mediating the increased HSPC response. In view of the chronic, stable phase of the CVD, the absence of left ventricular failure and the use of b-blockers in the patients included in the present study, these acute stimuli are less likely to be major contributors in our patients. Alternative causal pathways comprise persistent effects of an ischaemic event on senescent stem cells, 25 or a potential role of atherosclerotic risk factors on HSPCs. 26 In this respect, we observed a significant correlation between plasma LDLc concentration and metabolic activity in haematopoietic tissues lending further support to a direct role of elevated LDLc in mediating bone marrow hyper-responsiveness. Several studies detailed an interaction between lipoproteins and the myeloid lineage, both of upstream as well as downstream, differentiated cells. 26 Regarding the differentiated cells, mice with high-fat diet induced hypercholesterolaemia display a marked expansion of pro-inflammatory monocytes. 27 In parallel, patients with significantly elevated LDL levels are also characterized by an increased number of proatherogenic monocytes 28 as well as arterial wall inflammation 29 compared with subjects with normal cholesterol levels. With respect to the myeloid progenitors, murine studies have showed that elevated cholesterol levels increased the number of HSPCs in the blood 30, 31 as well as the bone marrow. 32 In a large community-based study, the number of circulating CD34+ cells in humans correlated also positively with total cholesterol levels. 33 Conversely, a reduction in cholesterol levels via statin therapy was followed by a reduction in circulating HSPCs in patients. 34 Oxidized lipoproteins affect haematopoietic stem and progenitor cells function and phenotype
Besides the relation between lipids and HSPC number, we also addressed the potential impact on HSPC functionality. First, oxLDL was found to increase the CFU-GM capacity of the HSPCs, whereas nLDL had no effect. The monoclonal antibody E06, which blocks the PC headgroup of oxidized phospholipids, 13 -15 abolished this effect of oxLDL. Oxidized phospholipids represent danger-associated molecular patterns which can be recognized by multiple innate pattern recognition receptors, 35 igniting a variety of pro-inflammatory and plaque destabilizing processes. 35 -37 Secondly, oxLDL also promoted the myeloid differentiation bias of HSPCs of healthy donors, evidenced by the increased expression of the monocytic cell markers CD14 and CD16. This is of specific interest, since HSPC-derived monocytes and macrophages are key cellular effectors in atherosclerosis. 38 In addition, we also observed an increased expression of CCR2 on progenitor cells, which is elementary on upstream haematopoietic precursors contributing to myelopoiesis following ischaemic organ injury. 39 Interestingly, a CCR2-positive subset was also present in patients with CVD, whereas this subset had a profound higher proliferative rate and displayed a myeloid differentiation bias. 39 Whereas the latter study examined CCR2 + progenitors in the setting of an acute ischaemic event, 39 our findings underscore the need to evaluate these pathways also in the setting of chronic atherosclerosis.
Study limitations
Several limitations need to be acknowledged. First, due to ethical constraints for clinical research, PET imaging and HSPCs studies were not performed in the same patients. The clinical characteristics, including age, gender, BMI, time post event, and medication use, however, were comparable between the CVD patients in both studies (see Supplementary material online, Table S3 ). Nevertheless, extrapolation and generalizability of our findings are limited. In addition, the relative small sample sizes restrain correlation analysis, with among others inflammatory biomarkers. Secondly, regarding the HSPCs ex vivo assays, we acknowledge that the manner of harvesting (G-CSF), the retrospective nature as well as the type, stage, and (pre)treatment of the cancer and statin treatment in the CVD group are confounding variables. Also, a potential causal or accelerating effect of the presence of cancer on ischaemic events cannot be excluded. In order to minimize the impact of these effects, however, we carefully matched patients and controls for disease and therapy specifications and only included patients with significant atherosclerotic disease (elevated CAC scores and/or significant carotid artery stenosis). Thirdly, the design of the studies, i.e. harvested HSPCs, precludes repetitive assessments of haematopoietic activity within patients over time. Finally, although we observed a significant interaction between oxidized lipoproteins and HSPC function and phenotype, the present study cannot address causality or consequence of this mechanism in vivo.
Conclusions
Whereas during the past decade downstream myeloid cells, mostly monocytes and macrophages, have been studied intensively in
Increased haematopoietic activity in atherosclerosis atherogenesis, the interest in the more upstream HSPCs and their involvement in atherogenesis is expanding. 40 The present experimental work describes that (i) haematopoietic tissues are more active in patients with atherosclerotic disease, (ii) HSPCs are functionally different in these patients, and (iii) potentially affected by oxidized lipoproteins. Further translational research is needed to dissect the interactions between up-and downstream cells and the drivers of chronic low-grade inflammation in human atherogenesis.
